Does Hormone Replacement Therapy Cause Cancer

Hormone replacement therapy raises the risk of some cancers, does not appear to raise the risk of others, and the answer changes depending on which hormones are used, how they are delivered, how long they are taken, and how old a woman is when she starts. There is no single answer that covers every cancer and every woman.

Below we go through breast, endometrial, ovarian, colorectal, and cervical cancer one at a time, with the numbers behind each. We then cover why estrogen affects some tissues and not others, what happens to risk after stopping, how hormone therapy affects mammogram results, and what a woman can actually do to keep her risk as low as possible.

Does Hormone Replacement Therapy Cause Cancer?

Hormone replacement therapy raises the risk of certain cancers and not others, and the degree of risk depends on which hormones are used, how they are given, for how long, and whether a woman still has her uterus. The American Cancer Society frames it exactly this way, and adds that hormone therapy is likely a safe option for healthy women with bothersome menopausal symptoms who are under 60 or within ten years of menopause and who do not have conditions such as breast cancer, heart disease, a history of stroke or blood clots, or liver disease.

Two forms of therapy drive nearly all the differences. Estrogen therapy, often shortened to ET, means estrogen taken alone. Estrogen-progestin therapy, shortened to EPT, means estrogen combined with progesterone or a progestin. Those two produce different cancer patterns, and confusing them is the single most common reason women get this topic wrong.

It is also worth knowing where the authorities stand. The American Cancer Society states plainly that it holds no position or guidelines on menopausal hormone therapy. That is not evasion. It reflects that the decision depends on an individual balance of symptoms, baseline risk, and preferences rather than on a general rule, which is the same reason a hormonal imbalance is assessed person by person rather than by protocol.

Does HRT Cause Breast Cancer?

Combined estrogen-progestin therapy is linked to a higher risk of breast cancer in postmenopausal women over age 60, and the risk increases further when the therapy is used for more than ten years. The American Cancer Society reports this directly, and also notes that short-term use, meaning less than about four years with no prior estrogen use, is not thought to increase breast cancer risk.

Duration and age are the two levers. Breast Cancer Research Foundation summarizes the 20-year follow-up to the Women's Health Initiative as finding that breast cancer risk rose with longer use of combined therapy, that the absolute risk stayed low compared with placebo, and that women aged 50 to 59 had lower risk than women 60 and older. A separate large United Kingdom study of women aged 50 to 79 found the same pattern, with higher risk tied to longer use and no increased risk from short-term past use of under five years.

Family history changes the starting point rather than the therapy's effect. A woman with a strong family pattern of breast or ovarian cancer begins from a higher baseline, so the same small relative increase produces a larger absolute number. Formal genetic screening is how that baseline gets established rather than guessed at.

How Much Does HRT Raise Breast Cancer Risk?

The Women's Health Initiative found three additional cases of invasive breast cancer per 1,000 women among those aged 50 to 59 who took oral estrogen plus progestin for five years, according to MD Anderson Cancer Center. Read another way, the same trial produced 38 breast cancers per 10,000 women per year on combined therapy compared with 30 per 10,000 on placebo.

Longer exposures produce larger numbers. A collaborative reanalysis pooling 51 studies, covering 52,705 women with breast cancer and 108,411 without, found that hormone therapy used for more than five years was associated with roughly a 30 percent increase in relative breast cancer risk. Relative increases of that size still translate into small absolute numbers for most individual women, which is why both figures belong in the conversation.

Two further findings from the American Cancer Society deserve a place here. Breast cancers found in women taking combined therapy are more likely to be larger and more advanced. Combined therapy also increases breast density, which affects risk in its own right and makes mammograms harder to read.

Does Estrogen Alone Cause Breast Cancer?

Estrogen taken alone has not been linked to higher breast cancer risk in women using it for shorter periods, and the evidence on longer use and on whether it lowers risk is genuinely mixed. This is the point where reputable sources disagree with each other, so it is worth laying out what each one says.

The American Cancer Society reports that estrogen therapy has not been linked to a higher risk of breast cancer in shorter-term users, that it may slightly lower the risk, and that some long-term studies have suggested increased risk in women who took it for more than ten years. Breast Cancer Research Foundation goes further, describing the 20-year Women's Health Initiative follow-up as showing that estrogen-only therapy lowered breast cancer risk in women with prior hysterectomies across all age groups studied.

MD Anderson takes a more cautious line. Writing as a breast medical oncologist, Dr. Carlos Barcenas describes the hormones used in hormone replacement therapy, estrogen and progesterone, as linked to several cancers including breast and endometrial cancer, with risk rising the longer the therapy is used.

We are not going to resolve a disagreement between the American Cancer Society, a breast cancer research foundation, and a comprehensive cancer center. What the disagreement tells a reader is useful on its own: estrogen alone behaves differently from combined therapy on breast tissue, the direction of that difference is still being worked out, and any source stating the matter with total confidence is overstating the evidence.

Does HRT Cause Endometrial Cancer?

Yes, estrogen taken alone raises the risk of endometrial cancer in women who still have a uterus, and this is the clearest cancer risk in the entire topic. The American Cancer Society is unambiguous about the mechanism and the consequence.

Estrogen taken alone thickens the lining of the uterus. A thickened uterine lining can progress to hyperplasia, meaning an overgrowth of cells, which can cause abnormal vaginal bleeding and over time raise endometrial cancer risk. Hyperplasia is the step that can develop into cancer, and the American Cancer Society notes the elevated risk remains higher even after estrogen therapy is stopped.

Adding a progestin removes that added risk. When estrogen is given together with a progestin, endometrial cancer risk is not increased, because the progestin protects the uterine lining from thickening. That is the entire reason combined therapy exists and the reason women who still have a uterus are prescribed both hormones rather than estrogen alone.

One consequence of this is worth acting on rather than just knowing. Any vaginal bleeding after menopause should be reported to a doctor promptly, because it can be a symptom of endometrial cancer. The American Cancer Society makes that point specifically, and adds that women on combined therapy do not carry a higher endometrial cancer risk but can still develop the disease.

Does HRT Cause Ovarian Cancer?

Both estrogen therapy and combined estrogen-progestin therapy are linked to a small increase in ovarian cancer risk, mainly while the therapy is actively being taken. The American Cancer Society reports this for both forms.

Duration and timing shape the size of it. Overall risk rises the longer the therapy is used but remains low in absolute terms, and the risk declines over time once the therapy is stopped. Ovarian cancer is uncommon to begin with, so a small relative increase on a small baseline stays a small number.

Ovarian cancer receives less attention in this conversation than breast or endometrial cancer, partly because the effect is smaller and partly because no reliable screening test exists for it in average-risk women. Family history matters more here than for most cancers on this list.

Does HRT Cause Colorectal Cancer?

Hormone replacement therapy does not appear to increase colorectal cancer risk, and some long-term studies suggest estrogen therapy is associated with a lower risk. This is where the pattern runs in the opposite direction from breast and endometrial cancer.

The American Cancer Society reports that estrogen therapy does not appear to raise colorectal cancer risk and that some long-term studies suggest a lower risk. For combined therapy, the overall risk does not appear to rise, though the American Cancer Society notes that colorectal cancers found in women taking combined therapy may be more advanced when detected.

The Women's Health Initiative found 6 fewer colorectal cancers per 10,000 women-years on combined therapy compared with placebo, alongside the increases in other outcomes. A lower risk in one column does not offset a higher risk in another, and colorectal cancer risk is influenced heavily by factors unrelated to hormones. Screening adherence, activity level, and nutrition support all carry more weight for this particular cancer than hormone status does.

Does HRT Cause Cervical Cancer?

Hormone replacement therapy does not appear to increase overall cervical cancer risk, and a 2025 meta-analysis found it associated with lower overall risk while also finding more cytological abnormalities and a possible increase in one specific subtype. This one requires care to read correctly.

A systematic review and meta-analysis published in Frontiers in Oncology in July 2025 pooled nine observational studies. Current and persistent hormone therapy use was associated with an odds ratio of 0.70 for cervical cancer overall, and 0.51 for squamous cell carcinoma, both pointing toward lower risk. Cervical adenocarcinoma showed an odds ratio of 1.82, pointing toward higher risk, though the confidence interval crossed the line of no effect. Any cytological abnormality showed an odds ratio of 1.38, pointing toward more abnormal Pap results.

The authors themselves caution against reading the protective figure as a drug effect. They attribute much of it to the likelihood that women on hormone therapy attend more frequent gynecological follow-up and cervical screening, which allows precancerous lesions to be found and treated earlier. They also note the included studies were published between 1997 and 2009 and that the total number of studies was small. Their own conclusion is that hormone therapy does not increase overall cervical cancer risk but may raise the risk of the adenocarcinoma subtype and is associated with cancer-related cytological changes.

Cancer TypeDirection of RiskWhat Drives ItStrength of EvidenceWhat Reduces ItBreastHigher with combined therapy, especially over 60 and beyond 10 years; mixed for estrogen aloneHormone stimulation of breast tissue; duration of exposureStrong for combined therapy; mixed and debated for estrogen aloneShorter duration, starting before 60, stopping when no longer neededEndometrialHigher with estrogen alone in women with a uterus; not increased with combined therapyEstrogen thickening the uterine lining without progestin oppositionStrong and long establishedAdding a progestin; reporting postmenopausal bleeding promptlyOvarianSmall increase with both forms, mainly during active useHormone exposure of ovarian tissueModerate; absolute risk stays lowShorter duration; risk declines after stoppingColorectalNot increased; some studies suggest lower with estrogen aloneNot primarily hormone drivenModerateColonoscopy on schedule; activity and dietCervicalNot increased overall; more abnormal Pap results; possible increase in adenocarcinoma subtypeHPV is the primary driver; adenocarcinoma appears hormone sensitiveLimited; older studies, small pool, likely screening biasRegular cervical screening; HPV vaccination where appropriate

Sources: American Cancer Society, Menopausal Hormone Therapy and Cancer Risk (revised January 2026); Women's Health Initiative; MD Anderson Cancer Center; Breast Cancer Research Foundation; Frontiers in Oncology systematic review and meta-analysis (2025).

Why Does Estrogen Affect Some Cancers and Not Others?

Estrogen affects some cancers and not others because tissues differ in how many estrogen receptors they carry and in what estrogen does once it binds to them. The pattern in the table above is not random.

Receptors explain the breast pattern. Most breast cancers are hormone-receptor positive, meaning the cancer cells carry receptors that respond to estrogen by growing. Breast Cancer Research Foundation notes that hormone replacement therapy can stimulate the growth of hormone-receptor-positive breast cancer, which is the biological reason it is avoided in women with that history.

Proliferation explains the endometrial pattern. Estrogen tells the uterine lining to build up, which is its normal job during a menstrual cycle. Without a progestin to trigger shedding, that building continues, and continuous proliferation is what raises cancer risk over years.

Colorectal and cervical tissue behave differently again. Colorectal cancer is driven mainly by factors other than sex hormones. Cervical cancer is driven primarily by human papillomavirus infection, and the meta-analysis authors suggest estrogen's effects on local immune surveillance may partly explain why squamous cell carcinoma trends downward while adenocarcinoma, which shows estrogen-receptor positivity more like endometrial cancer, trends the other way.

Hormone exposure from outside the body is only one input into any of this. Endocrine-disrupting chemicals, heavy metals, and pesticides also interact with hormone receptors, and our work in environmental medicine looks at that exposure alongside prescribed hormones rather than in isolation.

Does Cancer Risk Go Away After Stopping HRT?

Breast cancer risk returns to average within about three years of stopping hormones, and ovarian cancer risk also declines after stopping. The American Cancer Society gives the three-year figure for breast cancer directly.

Not every risk reverses the same way. The American Cancer Society notes that the endometrial cancer risk from estrogen taken alone remains higher even after the therapy is stopped, which makes it the exception on this list. Ovarian cancer risk goes down over time once therapy ends.

Reversibility follows the mechanism. Risks that depend on active hormone stimulation of tissue fade once the stimulation stops. Risks that come from a structural change already laid down in tissue do not fade the same way. That distinction is worth raising with a prescriber when weighing how long to continue.

Stopping is not automatically the safer choice either. Estrogen loss carries its own consequences for bone and cardiovascular health, and healthy aging involves weighing several risks against each other rather than minimizing one in isolation.

Does HRT Affect Mammogram Results?

Yes, combined estrogen-progestin therapy increases breast density, which affects cancer risk on its own and makes mammograms harder to read. The American Cancer Society names both effects together.

Denser breast tissue appears white on a mammogram, and so do tumors, which reduces the contrast a radiologist relies on. That is why hormone therapy makes screening adherence more important rather than less. The American Cancer Society advises women on hormone therapy to follow guidelines for early cancer detection, with particular attention to breast cancer screening, and MedlinePlus-style guidance on hormone products likewise calls for a yearly physical including breast examination and mammogram.

A workable screening pattern while on hormone therapy looks like this:

1. Tell the radiology facility you are taking hormone therapy, so prior images can be compared with that context in mind.
2. Keep mammograms on the schedule your provider sets rather than stretching the interval.
3. Ask whether your breast density warrants additional imaging, since some women with dense tissue benefit from ultrasound or MRI alongside mammography.
4. Report any new breast lump, skin change, or nipple discharge right away rather than waiting for the next scheduled scan.
5. Report any vaginal bleeding after menopause promptly, since it can signal endometrial cancer.
6. Keep cervical screening current, given the association with abnormal cytology results.
7. Review the whole picture with your provider at least yearly, including whether continuing therapy still makes sense.

Screening adherence is the part of this that a woman controls completely, and among the patients we see across Oakland County it is also the part most often allowed to slip during a busy decade of life. Our advanced lab testing covers hormone metabolites and how a woman processes hormones, and it complements imaging-based cancer screening rather than replacing any part of it.

Can You Take HRT After Breast Cancer?

Systemic hormone replacement therapy of any kind is not currently recommended for women with a history of breast cancer. Breast Cancer Research Foundation states this directly, and MD Anderson agrees, noting that hormone replacement therapy is not recommended after hormone-receptor-positive breast cancer and that in general it is preferred that women with any breast cancer history not receive it.

The evidence behind that position is unusually firm. A 2021 systematic review and meta-analysis found systemic hormone therapy significantly increased breast cancer recurrence risk in women with a history of the disease, especially hormone-receptor-positive disease. The HABITS trial, which tested hormone therapy after breast cancer directly, was stopped early because the risk to participants was judged unacceptable.

Local vaginal therapy is a different question and is being actively reconsidered. MD Anderson notes that in some cases vaginal estrogen cream may make sense for severe vaginal dryness, describing it as not a black and white situation. Breast Cancer Research Foundation cites a recent retrospective study in which vaginal estrogen use among women with a breast cancer history was associated with improved breast-cancer-specific and overall survival compared with non-users. That is retrospective evidence rather than a trial result, and it belongs in a conversation with an oncologist rather than in a decision made alone.

Women in this situation have non-hormonal options for symptoms, and both sources list several. Managing symptoms without hormones is genuinely harder, and the trade-off is real. For women without a cancer history who are weighing options, our discussion of menopause symptom relief covers the alternatives in more depth.

Are Bioidentical Hormones Safer for Cancer Risk?

Bioidentical hormones have not been shown to be safer for cancer risk than other forms of hormone therapy, and compounded bioidentical preparations should be assumed to carry at least the same risks. The American Cancer Society is direct on this point, and we think it is important to state it plainly rather than soften it.

Two different things get called bioidentical. The first is a description of molecular structure, meaning a hormone with the same chemical structure as one the body makes. Estradiol and micronized progesterone fit that description and are available in FDA-approved prescription products. The second usage refers to hormone combinations custom mixed by compounding pharmacies, often with doses set from blood or saliva testing.

The American Cancer Society draws a sharp line around the second category. Compounded products are not tested for quality or safety by the FDA, there are no long-term studies showing they are safer or cause fewer side effects, and for that reason they should be assumed to have at least the same health risks as any other form of menopausal hormone therapy. Marketing them as more natural, the American Cancer Society notes, can make them seem safer than they have been shown to be.

On the specific question of progesterone type, the evidence is suggestive and unsettled. The American Cancer Society reports that the type of progestin may affect breast cancer risk, with synthetic versions such as medroxyprogesterone acetate showing higher risk compared with micronized progesterone, which may be safer, and then adds that more study is needed. That is a hedged comparison between two options, not evidence that any hormone therapy lowers cancer risk. We are not aware of reliable evidence that any form of hormone therapy reduces breast cancer risk, and we would treat any claim to that effect with caution.

Our bioidentical hormone therapy protocols favor FDA-approved preparations where they fit a woman's needs, use delivery methods that hold levels steady and allow dose adjustment, and avoid hormone pellets because a pellet cannot be adjusted once placed. None of that makes hormone therapy risk free, and we would rather a patient hear that from us than from a search result.

Why Have Some Doctors Been Cautious About HRT?

Some doctors have been cautious about hormone replacement therapy because a large trial published in 2002 was halted over increased risks, and its findings were applied broadly across products, doses, and age groups. Breast Cancer Research Foundation describes what followed as women and their doctors largely abandoning the treatment.

The trial was the Women's Health Initiative, and it tested one oral formulation in a population whose average age was well past menopause. A boxed warning was added to many hormone products afterward covering uterine and breast cancer, stroke, blood clots, and dementia in women over 65. In November 2025 the FDA announced it would initiate removal of the cardiovascular, breast cancer, and probable dementia language from those boxed warnings.

Two details keep that accurate. The FDA did not request removal of the cardiovascular disease and breast cancer risks from the Warnings and Precautions section of the labeling, so those risks remain on the label elsewhere. The agency is also not requesting removal of the endometrial cancer boxed warning on systemic estrogen-alone products, for the reason described earlier in this article.

Caution and refusal are different things. MD Anderson describes hormone therapy decisions as made case by case, weighing age, health history, and symptoms, and a naturopathic medicine approach works the same way, which means sometimes recommending against hormone therapy for a particular woman.

What Lowers Your Cancer Risk While on HRT?

You lower your cancer risk while on hormone therapy by matching the therapy to your anatomy, using the lowest effective dose for the shortest time that meets your needs, keeping every screening appointment, and addressing the risk factors that have nothing to do with hormones. Several of these move the numbers more than the hormone decision itself does.

Matching the therapy to anatomy is the first and largest step. A woman with a uterus taking systemic estrogen needs a progestin, and that single addition removes the added endometrial cancer risk entirely. A woman whose only symptoms are vaginal needs low-dose vaginal therapy rather than systemic therapy, and the American Cancer Society notes that little hormone from local products enters the bloodstream. Getting that match right is the first thing we settle when planning bioidentical hormones for a patient.

The non-hormonal risk factors are where most of the achievable reduction sits. Alcohol, excess body weight, physical inactivity, and smoking all raise breast and other cancer risks independently of hormone therapy, and body weight matters here for a specific reason: after menopause, estrone produced in fat tissue becomes a meaningful source of estrogen exposure. Practical steps include:

• Take a progestin if you still have a uterus and are using systemic estrogen
• Use low-dose vaginal therapy when vaginal symptoms are the only complaint
• Use the lowest dose that controls your symptoms, and revisit whether you still need it
• Keep mammograms, cervical screening, and colonoscopy on schedule
• Report postmenopausal bleeding, new breast changes, or nipple discharge without waiting
• Reduce alcohol intake, which raises breast cancer risk on its own
• Stay physically active and maintain a weight that is healthy for you
• Do not smoke or use tobacco
• Establish your family history and baseline risk before starting rather than after

Establishing that baseline is the step most often skipped. At our Bingham Farms office we look at family history, hormone metabolites, how a woman processes hormones, inflammatory markers, and environmental exposures before any protocol is designed, because two women with identical symptoms can carry very different baseline risks. Our hormone therapy planning starts there rather than with a prescription.

Nothing in this section replaces oncology or cancer screening. It sits alongside them. A woman with a personal or strong family history of a hormone-sensitive cancer belongs in a conversation with an oncologist or genetic counsellor as well as with whoever manages her hormones.

For women who are appropriate candidates, that groundwork is what makes the therapy as safe as it can reasonably be. Our holistic care model treats screening adherence and modifiable risk factors as part of the hormone plan rather than as separate concerns.

Frequently Asked Questions

Is HRT the Same as Hormone Therapy for Cancer?

No, hormone replacement therapy and hormone therapy for cancer work in opposite directions. Breast Cancer Research Foundation and MD Anderson both make this point explicitly. Hormone therapy for breast cancer, also called endocrine therapy, lowers hormone levels or blocks hormone action to reduce recurrence risk, using drugs such as tamoxifen and aromatase inhibitors. Hormone replacement therapy adds estrogen and progesterone back to relieve menopause symptoms.

What Can I Do Instead of HRT for Menopause?

Alternatives to hormone therapy include non-hormonal prescription medications for hot flashes, cognitive behavioural therapy, acupuncture, yoga, and vaginal moisturizers and lubricants for dryness. The American Cancer Society notes that some antidepressants at low doses reduce hot flashes by acting on temperature-control pathways, and that newer medications target those pathways directly. These options do not help with bone loss the way estrogen does.

Is Hormone Therapy Worth the Risk?

Whether hormone therapy is worth the risk depends on how much your symptoms affect your life, your baseline cancer risk, your age, and how long ago you reached menopause. The American Cancer Society lists exactly these as the factors to weigh and holds no general position either way. For a woman with severe symptoms, low baseline risk, and recent menopause, the balance often favours treatment. For a woman with a breast cancer history, it does not.

Does Vaginal Estrogen Raise Cancer Risk?

It is not clear whether low-dose vaginal estrogen changes cancer risk, and the American Cancer Society says so directly. Low-dose vaginal products raise estrogen levels much less than pills or patches, and little of the hormone enters the bloodstream. The American Cancer Society advises women using vaginal creams, rings, or tablets to discuss follow-up and any possible need for progestin with their doctor.

Does HRT Cause Cancer to Grow Faster?

Hormone replacement therapy can stimulate the growth of hormone-receptor-positive breast cancer, according to Breast Cancer Research Foundation, which is why it is avoided in women with that history. The American Cancer Society also notes that breast cancers found in women on combined therapy tend to be larger and more advanced, and that colorectal cancers found in those women may be more advanced.

How Long Can You Safely Take HRT?

There is no fixed safe duration, though breast cancer risk on combined therapy rises with use beyond about five years and further beyond ten. MD Anderson notes it is generally recommended that patients stop by age 60 so that risks decline, while the American Cancer Society frames duration as an individual decision made with a doctor and revisited over time. Regular review matters more than any particular number of years.

Wrapping It Up

Hormone replacement therapy does not have one relationship with cancer. Estrogen taken alone clearly raises endometrial cancer risk in women who still have a uterus, and adding a progestin removes that risk. Combined therapy raises breast cancer risk with longer use and in older women, with the Women's Health Initiative finding three additional invasive breast cancers per 1,000 women aged 50 to 59 over five years. Both forms carry a small increase in ovarian cancer risk during active use. Colorectal cancer risk does not appear to rise and may fall. Cervical cancer risk does not appear to rise overall, though abnormal Pap results are more common and one subtype may behave differently.

Three facts do most of the practical work. Breast cancer risk returns to average within about three years of stopping. Route and preparation change the numbers measurably. And the risk factors that have nothing to do with hormones, including alcohol, body weight, activity, smoking, and screening adherence, are often where the largest achievable reduction sits. Hormone therapy is not risk free, and no form of it has been shown to lower cancer risk. What it can be, for the right woman, is a well-monitored decision made with a clear view of her own baseline.

If you are trying to weigh this for yourself and want your actual baseline risk established before anyone writes a prescription, we would be glad to work through it with you. Cutler Integrative Medicine has helped women think through hormone decisions for over fifteen years, and we work alongside your other providers rather than in place of them. Our practice is based in Bingham Farms.

You are welcome to schedule a consultation whenever the timing suits you.